Common Contracts
4 similar Employment Agreement contracts by MBX Biosciences, Inc., Bicara Therapeutics Inc.
EMPLOYMENT AGREEMENTEmployment Agreement • August 30th, 2024 • MBX Biosciences, Inc. • Pharmaceutical preparations
This Employment Agreement (“Agreement”) is made between MBX Biosciences, Inc., a Delaware corporation (the “Company”), and Richard Bartram (the “Executive”) and is effective as of the closing of the Company’s first underwritten public offering of its equity securities (the “IPO”) pursuant to an effective registration statement under the Securities Act of 1933, as amended (the “Effective Date”). Except with respect to the Restrictive Covenants Agreement and the Equity Documents (each as defined below), this Agreement supersedes in all respects all prior agreements between the Executive and the Company regarding the subject matter herein, including without limitation (i) the Employment Agreement between the Executive and the Company dated March 16, 2022 (the “Prior Agreement”), and (ii) any other offer letter, employment agreement or severance agreement.
EMPLOYMENT AGREEMENTEmployment Agreement • August 30th, 2024 • MBX Biosciences, Inc. • Pharmaceutical preparations
This Employment Agreement (“Agreement”) is made between MBX Biosciences, Inc., a Delaware corporation (the “Company”), and Salomon Azoulay (the “Executive”) and is effective as of the closing of the Company’s first underwritten public offering of its equity securities (the “IPO”) pursuant to an effective registration statement under the Securities Act of 1933, as amended (the “Effective Date”). Except with respect to the Restrictive Covenants Agreement and the Equity Documents (each as defined below), this Agreement supersedes in all respects all prior agreements between the Executive and the Company regarding the subject matter herein, including without limitation (i) the Employment Agreement between the Executive and the Company dated June 14, 2024 (the “Prior Agreement”), and (ii) any other offer letter, employment agreement or severance agreement.
EMPLOYMENT AGREEMENTEmployment Agreement • August 30th, 2024 • MBX Biosciences, Inc. • Pharmaceutical preparations
This Employment Agreement (“Agreement”) is made between MBX Biosciences, Inc., a Delaware corporation (the “Company”), and P. Kent Hawryluk (the “Executive”) and is effective as of the closing of the Company’s first underwritten public offering of its equity securities (the “IPO”) pursuant to an effective registration statement under the Securities Act of 1933, as amended (the “Effective Date”). Except with respect to the Restrictive Covenants Agreement and the Equity Documents (each as defined below), this Agreement supersedes in all respects all prior agreements between the Executive and the Company regarding the subject matter herein, including without limitation (i) the Employment Agreement between the Executive and the Company dated July 8, 2020 (the “Prior Agreement”), and (ii) any other offer letter, employment agreement or severance agreement.
SECOND]1 AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • August 22nd, 2024 • Bicara Therapeutics Inc. • Pharmaceutical preparations • Massachusetts
This [Second]2 Amended and Restated Employment Agreement (“Agreement”) is made between Bicara Therapeutics Inc., a Delaware corporation (the “Company”), and [Name] (the “Executive”), and is effective commencing on [ ] (the “Effective Date”). Except with respect to the Equity Documents and Restrictive Covenants Agreement (both as defined below) and subject to Section 11 below, this Agreement supersedes in all respects all prior agreements between the Executive and the Company regarding the subject matter herein, including without limitation (i) the employment agreement between the Executive and the Company dated [ ], [as amended by the First Amendment to Employment Agreement dated [ ],and the Amended and Restated Employment Agreement dated [ ]]3 (collectively, the “Prior Agreements”), and (ii) any other offer letter, employment agreement or severance agreement.
